Fractionation in Boron Neutron Capture Therapy

  • K. R. Durrant
  • J. Hopewell
Part of the Basic Life Sciences book series (BLSC, volume 50)


The theoretical basis has been described for the value of BNCT in the treatment of cerebral glioblastoma multiforme.1 Early clinical trials in the United States showed unexpected and excessive damage to normal brain tissue. Subsequent analysis suggests that this damage was due to high levels of boron in blood at the time of irradiation. After modification of the technique, Hatanaka2 demonstrated that the method is effective, with 30% of the patients in his study surviving five years. This is a striking result in the treatment of a tumor, where a 95% two-year mortality and 100% five-year mortality can be expected after treatment by conventional photon radiation therapy.3 It also is clear that some patients tolerated the treatment without gross intellectual damage, although data on normal tissue damage in this series is incomplete.


Neutron Beam Late Toxicity Boron Neutron Capture Therapy Relative Biological Effectiveness Boron Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. G. Zamenhof, B. W. Murray, G. L. Brownell, G. R. Wellum, and E. I. Tolpin, Boron neutron therapy for the treatment of cerebral gliomas, Med. Phys. 2: 47 (1975).Google Scholar
  2. 2.
    H. Hatanaka, K. Amano, S. Kamano, and K. Sano, Clinical experience of boron neutron capture therapy for malignant brain tumors (1968–1985), in: “Neutron Capture Therapy,” H. Hatanaka, ed., Nishimura, Tokyo (1986).Google Scholar
  3. 3.
    M. D. Walker, S. B. Green, and D. P. Byar, Randomized comparison of radiotherapy and nitrosoureas for malignant gliomas after surgery. N. Eng. J. Med. 303: 1323 (1980).CrossRefGoogle Scholar
  4. 4.
    M. Strandquist, Studien ube die Kumulative Wirkung der Roentgenstrahlen bei Fraktionierung. Acta Radiol. (Suppl) 55: 1 (1944).Google Scholar
  5. 5.
    M. M. Elkind, H. Sutton-Gilbert, W. B. Moses, T. Alescio, and R. W. Swain, Radiation response of mammalian cells in culture, Radiat. Res. 25: 359 (1965)Google Scholar
  6. 6.
    F. Ellis, Dose, time and fractionation: a clinical hypothesis. Clin. Radiol. 20: 1 (1969).PubMedCrossRefGoogle Scholar
  7. 7.
    J. W. Hopewell, D. W. H. Barnes, M. E. C. Robbins, J. M.Samson, J. T. Knowles, and G. J. M. J. van den Aardwig, The relative biological effectiveness of fractionated doses of fast neutrons for normal tissues in the pig. Brit. J. Radiol. (in press).Google Scholar
  8. 8.
    A. B. Miller, B. Hoogstraten, M. Staquet, and M. D. Winkler, Report: results of cancer treatment. Cancer 47: 207 (1981).PubMedCrossRefGoogle Scholar
  9. 9.
    B. J. Allen, J. K. Brown, and B. Harrington, Neutron capture therapy research for malignant melanoma, in: “Neutron Capture Therapy,” H. Hatanaka, ed., Nishimura, Tokyo (1986).Google Scholar
  10. 10.
    J. F. Fowler, R. L. Morgan, and J. A. Silvester, Experiments with fractionated x-ray treatment of the skin of pigs. Br. J. Radiol. 36: 188 (1963).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • K. R. Durrant
    • 1
  • J. Hopewell
    • 1
  1. 1.The Churchill HospitalOxfordEngland

Personalised recommendations